Add to watchlist:

Only registered members can add into watchlist !

Register here !
Deal NanoViricides Tax Free* Losses can exceed
your initial deposit
*subject to change and depends on individual circumstances.

NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.


NanoViricides armed with $18 mln of cash after retirement of Series C preferred stock

NanoViricides recently sold $6 million of its Series B convertible debentures to three family investment offices and a charitable foundation, and as a result, determined that the retirement of its preferred Series C stock was in the best interests of its shareholders.

NanoViricides (OTCBB: NNVC) says it has retired the remainder of its Series C convertible preferred stock previously purchased by Seaside 88 with a cash payment, and said it holds around $18 million of cash in hand following the transaction. 

The drug developer believes that these funds are sufficient, it said, for more than two years of operating expenses, and to advance its anti-flu drugs into initial human clinical trials. 

The deal with Seaside 8 was done through a mutual agreement, NanoViricides added. 

Shares of the company rose almost 10% in early deals Thursday, to 48.3 cents. 

"We have been very happy with the strong financial support that Seaside has provided to the company," said chairman Anil R. Diwan, adding that Seaside has invested a total of $25 million into the company over the past few years. 

"Their funding has allowed us to focus on drug development without any fund-raising distractions. We have been able to advance our influenza drug pipeline with the use of this financing. Further, we have been able to obtain sufficient capital to fund our upcoming studies through IND filing and initial human clinical trials."

NanoViricides recently sold $6 million of its Series B convertible debentures to three family investment offices and a charitable foundation, and as a result, determined that the retirement of its preferred Series C stock was in the best interests of its shareholders. 

Around $2 million of the $6 million it raised was used to retire the Series C shares, it added. 

The news, which was announced late Wednesday, came just a day after the company announced that the renovation of the facility for its new clinical-scale cGMP production plant has begun.

The company said Tuesday it reached “a new milestone” with the start-up of the renovation of its cGMP (current good manufacturing practice) facility, which is being designed to produce sufficient quantities of the drugs needed for human clinical trials that will test various nanoviricide drug candidates as they advance into the clinical pipeline.

NanoViricides' injectable anti-flu drug, NV-INF-1, is intended for use in hospitalized patients with the flu. The company said it believes it will be useable in immuno-compromised populations, and may receive an orphan drug classification for this indication. 

According to the drug maker, its oral anti-influenza drug candidate, NV-INF-2, may be the first ever nanomedicine drug of any kind that is active when administered orally. This drug is being developed for out-patient influenza cases, and may also be useful for the protection of health care workers.

Both drugs in its FluCide program have shown “very high effectiveness” in preclinical animal studies, NanoViricidesnoted, routinely showing substantial superiority to Tamiflu, the current standard of care. 

The FluCide drugs are intended for use against most types of flu viruses, including H1N1 or the “swine flu”, H3N2, novel strain, and bird flu. 

The drugs are based on NanoViricides' biomimetic technology, which mimicks the natural sialic acid receptors for the influenza virus on the surface of a nanoviricide polymeric micelle. The company noted that all flu viruses bind to the sialic acid receptors, even if they rapidly mutate. 

Including the FluCide program, the company said it currently has six commercially important drug candidates in its pipeline that together address a market size greater than $40 billion. Those include drugs for use against HIV, viral eye diseases, Herpes, and Dengue viruses.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.